ProShare Advisors
NBSE

ProShare Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

ProShare Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-26
Closed -$97K – 2378
2014
Q2 		$97K Buy
+26
New +$97.9K ﹤0.01% 2366

Other funds holding NBSE

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ProShare Advisors's NBSE Position: Q3 2014 in Review

ProShare Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2014, closing a stake of 26 shares — an estimated $97K sold.

ProShare Advisors first reported a position in NBSE in Q2 2014 and held it in 1 quarter. The position peaked at $97K in Q2 2014. 52 funds tracked by Wall St. Rank hold NBSE as of Q3 2014.

  • ProShare Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • ProShare Advisors sold 26 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2014, an estimated $97K.
  • ProShare Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2014 and held it in 1 quarter.
  • ProShare Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $97K in Q2 2014.
  • 52 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2014.

Based on ProShare Advisors's 13F filing for Q3 2014, filed 6 Nov 2014.